The TFCP2/Grainyhead family of transcription factors has very ancient origins; these factors can be found throughout Metazoa and in fungi. Their DNA-binding domains have a characteristic, immunoglobulin-like structure, similar to that of the well documented tumor suppressor TP53. For this reason it was proposed that they are likely to represent an ancestor of TP53. In mammals, the TFCP2/Grainyhead family consists of two distinct subfamilies. One subfamily includes the Grainyhead-like 1-3 (GRHL1-3) proteins and the other consists of TFCP2 (synonyms: CP2, LSF, LBP-1c), TFCP2L1 (synonyms: CRTR-1, LBP-9) and UBP1 (synonyms: LBP-1a, NF2d9).
The TFCP2, TFCP2L1 and UBP1 proteins are very closely related. The amino acid sequences of TFCP2 and UBP1 share 88% identity, while TFCP2 and TFCP2L1 share 70% identity. Transcription factors TFCP2 and UBP1 are ubiquitously expressed, but the expression of TFCP2L1 is tissue- and developmentally-specific, being found primarily in embryonic stem cells, adult kidneys and several other tissues. These proteins are involved in various biological phenomena, including hematopoiesis, cell cycle control, regulation of expression of immune-related genes and cytochrome P450 genes. They have also been linked to Alzheimer's disease and to the regulation of human immunodeficiency virus (HIV). In recent years there has been a considerable increase in the number of publications reporting links between transcription factors from the TFCP2/Grainyhead family and various types of cancer. TFCP2 is a pro-oncogenic factor in hepatocellular carcinoma, pancreatic cancer and breast cancer, may be important in cervical carcinogenesis and in colorectal cancer. TFCP2 can also act as a tumor suppressor, for example, it inhibits melanoma growth. Furthermore, TFCP2 is involved in epithelial-mesenchymal transition and enhances angiogenesis. TFCP2L1 maintains pluripotency and self-renewal of embryonic stem cells and was implicated in a wide variety of cancers, including clear cell renal cell carcinoma, breast cancer and thyroid cancer[1][2][3].
FQI2-34 是一种口服有效的 TFCP2 (LSF) 小分子变构抑制剂,可直接结合 LSF 蛋白 (Ki = 63 nM),抑制 LSF 寡聚化,高效抑制其转录活性 (IC₅₀ = 48 nM),干扰 SF-DNA 相互作用,对 Huh7 细胞具有显著抗增殖活性,并在小鼠模型中诱导肿瘤消退,可用于肝癌研究。
GRHL1 Human Pre-designed siRNA Set A 包含针对 GRHL1(Human)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。
Grhl2 Rat Pre-designed siRNA Set A 包含针对 Grhl2(Rat)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。
GRHL3 Human Pre-designed siRNA Set A 包含针对 GRHL3(Human)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。
T7 Tag Peptide 是一种由 T7 噬菌体衣壳蛋白 gp 10 N-端 11 个残基组成的蛋白标签肽,可融合于增强型绿色荧光蛋白 (EGFP) 等蛋白质的 N 端或 C 端,并可用于不同的免疫检测以及亲和纯化。
T7 Tag Peptide TFA 是一种由 T7 噬菌体衣壳蛋白 gp 10 N-端 11 个残基组成的蛋白标签,可融合于增强型绿色荧光蛋白 (EGFP) 等蛋白质的 N 端或 C 端,并可用于不同的免疫检测以及亲和纯化。
TFCP2L1-IN-1 是一种靶向 TFCP2L1 活性区域并具有抗癌活性的特定小分子,与 Sorafenib (MS-X92288) 协同作用时可诱导细胞凋亡 (Apoptosis),并抑制肝癌细胞的增殖、侵袭、转移、克隆形成及球体形成能力。
UBP1 Human Pre-designed siRNA Set A 包含针对 UBP1(Human)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号